Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Shares Outstanding (Weighted Average): 2014-2025

Historic Shares Outstanding (Weighted Average) for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $116.2 million.

  • Coherus Oncology's Shares Outstanding (Weighted Average) rose 0.88% to $116.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.2 million, marking a year-over-year increase of 0.88%. This contributed to the annual value of $115.9 million for FY2024, which is 4.07% up from last year.
  • As of Q3 2025, Coherus Oncology's Shares Outstanding (Weighted Average) stood at $116.2 million, which was down 0.00% from $116.2 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Shares Outstanding (Weighted Average) ranged from a high of $116.2 million in Q2 2025 and a low of $75.8 million during Q1 2021.
  • In the last 3 years, Coherus Oncology's Shares Outstanding (Weighted Average) had a median value of $115.2 million in 2024 and averaged $106.7 million.
  • Data for Coherus Oncology's Shares Outstanding (Weighted Average) shows a peak YoY spiked of 43.18% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Coherus Oncology's Shares Outstanding (Weighted Average) stood at $76.8 million in 2021, then rose by 1.29% to $77.8 million in 2022, then soared by 43.18% to $111.4 million in 2023, then grew by 4.07% to $115.9 million in 2024, then climbed by 0.88% to $116.2 million in 2025.
  • Its last three reported values are $116.2 million in Q3 2025, $116.2 million for Q2 2025, and $115.9 million during Q1 2025.